Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Cephalon reports positive Amrix study results

Cephalon reports positive Amrix study results

15th February 2008

Cephalon has announced that new trial data demonstrates its once-daily, extended-release muscle relaxant Amrix to be superior to placebo.

Presented at the 24th American Academy of Pain Medicine Meeting in Orlando, the results showed Amrix to have a similar efficacy to thrice-daily cyclobenzaprine immediate-release (CIR) in alleviating acute muscle spasm associated with lower back and neck pain.

Additionally, Amrix was reported to induce less daytime drowsiness when compared to CIR.

Arnold J Weil, from Non-Surgical Orthopaedics, illustrated that most muscle relaxants were taken several times a day which can make it difficult for some patients to closely follow their treatment regimen.

However, he outlined: “With data supporting AMRIX as an effective once-daily treatment, health care professionals now have an easy-to-administer treatment option to offer their patients who are suffering from acute muscle spasm.”

The data was pooled from two identical 14-day trials which investigated just over 500 patients who had moderate-to-severe muscle spasm of cervical or lumbar origin.

Last month, Cephalon announced that it had received a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency for its breakthrough pain drug Effentora (fentanyl buccal tablet).

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.